NCT05456256Phase 2Recruiting

A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma

Study sponsor: Lantern Pharma Inc. · LTRN

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-12Estimated

Enrollment · participants90Estimated

Source updated2026-05-04Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-05-04 · 1 field changed

Primary completion date changed

− Before

~~Dec 2025~~

+ After

Dec 2026

Check registry source

Study details

Conditions studied

Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung

Treatments or interventions studied

LP-300DrugAlso known as Tavocept, BNP7787, Dimesna
PemetrexedDrugAlso known as Alimta, Pemfexy
CarboplatinDrugAlso known as Paraplatin

Primary outcomes · main study measures

Read the study measures

measure: Progression-free survival (PFS); description: Number of days or months from the date of randomization to the earliest of the documented disease progression based on the Response Evaluation Criteria in Solid Tumors (RECIST) V1.1 criteria; timeFrame: Through study completion, an average of 2 years; measure: Overall survival (OS); description: Number of days or months between the randomization date and the date of death from all causes; timeFrame: Through study completion, an average of 2 years

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history